CD8+肿瘤浸润淋巴细胞与高级别浆液性卵巢癌生存的剂量反应关联
结果显示HGSOC中CD8+肿瘤浸润淋巴细胞(TILs)数量与总生存显著相关,中位生存从无CD8+ TILs的2.8年增至高水平组的5.1年(趋势P=4.2×10⁻¹⁶)。
要点
- HGSOC中CD8+ TILs浸润最显著,且与总生存呈剂量反应关系。
- 无、低、中、高CD8+ TILs组中位生存分别为2.8、3.0、3.8、5.1年。
- 子宫内膜样和黏液性癌也见生存获益,其他组织学类型未见。
核心结论
- 本研究证实免疫浸润具有组织学类型特异性,并为CD8+ TILs与HGSOC生存之间的剂量反应关系提供了确切证据。
研究设计与样本
- 最终样本包括5577例女性,其中3196例为高级别浆液性卵巢癌,诊断时平均年龄58.4岁(中位58.2岁)。
主要发现
- 在5种主要浸润性组织学类型中,HGSOC显示最显著的CD8+ TILs浸润。
- HGSOC中CD8+ TILs与更长的总生存显著相关,无、低、中、高水平组的中位生存分别为2.8年、3.0年、3.8年和5.1年(趋势P=4.2×10⁻¹⁶)。
- 子宫内膜样癌和黏液性癌女性也观察到生存获益,但其他组织学类型未见。
- 在HGSOC中,无论细胞减灭术后残留病灶范围、已知标准治疗和胚系BRCA1致病突变状态如何,CD8+ TILs均为有利预后因素,但对BRCA2突变携带者无预后价值。
- 未分类CD8+ TIL计数评估显示接近对数线性的函数形式。
关键数值与推荐
- CD8+ TILs分组依据每高倍视野估计数量:阴性(无)、低(1-2)、中(3-19)、高(≥20)。
临床怎么用
- CD8+ TILs浸润程度(而非仅存在与否)对HGSOC具有预后价值,提示理解驱动浸润的因素是解析该癌症结局异质性的关键。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. OBJECTIVE: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. EXPOSURES: Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. MAIN OUTCOMES AND MEASURES: Overall survival time. RESULTS: The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. CONCLUSIONS AND RELEVANCE: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.
引用
- Goode EL, Block MS, Kalli KR, et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017. PMID: 29049607. doi:10.1001/jamaoncol.2017.3290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。